ROCHESTER, N.Y., May 5 — Carestream now offers an oncology reading workflow for PET/CT studies that equips clinicians with new native tools for its enterprise image management system  that deliver both quantitative and qualitative information to help improve and expedite the reading process.

More money than can be wisely allocated and properly coordinated has been pouring into lots of worthwhile projects in the wake of President Obama’s January establishment of the National Cancer Moonshot initiative to speed up cancer research. That’s a good problem to have, but it’s still a problem.

A readability analysis of 50 websites discussing treatment modalities for pancreatic cancer—one of the deadliest cancers and thus one of the most anxiety-producing after diagnosis—has found that, overall, the information is likely too hard to understand for vast swaths of the population.

An international phase 3 trial of patients with locally advanced, chemo-contained pancreatic cancer has found no significant difference in overall survival with chemoradiotherapy—a controversial treatment for this application—compared with chemotherapy alone. 

A new study supports the Choosing Wisely position that neuroimaging does not give worthwhile benefit to patients with screening-detected stage I non-small-cell lung cancer (NSCLC) but no symptoms of metastasis to the brain. However, the same study shows that many patients are receiving the imaging anyway.

Urologists from the University of California, Sand Diego School of Medicine have collaborated with Genesis Healthcare Partners to test a new model of care for managing low-risk prostate cancer patients, according to results of a study published in the journal Urology.

Researchers from the University of Birmingham in the United Kingdom have found that utilization of narrow band imaging can substantially reduce the risk recurrence from bladder cancer, according to results of a new study published in European Urology.

The use of MR and/or ultrasound imaging to systematically surveil individuals at high risk of developing pancreatic ductal adenocarcinoma (PDAC) due to their carrying of a mutation in the CDNK2A gene has proven worthwhile, as researchers in a European study were able to detect most PDACs at a resectable stage.